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ABSTRACT
Infections caused by Streptococcus pneumoniae are a worrisome public health 
problem worldwide. Young children and the elderly are the main age groups 
affected and the highest burden of the disease is found in developing countries. 
Pneumococcal infections cause 11% of the total infant deaths, representing the 
leading cause of child death currently preventable by vaccination. Epidemiologic 
information about pneumococci in Brazil is somehow restricted, but available data 
reinforce the worrisome occurrence of pneumococcal diseases, which are commonly 
treated empirically. Limitations in the diagnostic methods, along with the severity of 
disease contribute to this behavior. Thus, surveillance studies are crucial to define 
the prevalence of resistant strains both globally and in a particular region, as these 
strains may compromise empirical therapeutic choices. However, although different 
clones of penicillin non-susceptible pneumococci are internationally distributed, 
and considering diseases other than meningitis, the prevalence of resistance to 
penicillin is quite low, making this old, safe, and inexpensive drug an attractive first 
choice to treat pneumococcal infections. The widespread use of conjugate vaccines 
among children, influencing the circulation of resistant clones and the distribution 
of serotypes reinforces the need of surveillance studies to define the prevalence of 
resistance. 
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Infections caused by Streptococcus pneumoniae are a public health problem 
worldwide, especially considering young children and the elderly, and developing 
countries are clearly the most affected regions. Pneumococcal disease presents 
with a variable degree of severity, ranging from mild infections (acute otitis, 
sinusitis, and uncomplicated pneumonia) to invasive pneumococcal disease 
(IPD), such as bacteremic pneumonia and meningitis, which are associated 
with elevated morbidity and mortality, even when treated adequately. Indeed, 
case-fatality rates of pneumococcal meningitis can be as high as 37%1 and 
around 20% of survivors experience long-term disabling sequelae2.
Around 14.5 million episodes of severe pneumococcal disease occur 
annually in the world, causing 1,612,000 deaths3, 825,000 of them among 
children under 5 years old, representing 11% of the total number of infant 
deaths4. Indeed, pneumococcal infections are the leading cause of child 
death currently preventable by vaccination3. 
Epidemiologic information about pneumococcal disease is lacking in 
many parts of Latin America. Information is mostly based on laboratory 
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surveillance of S. pneumoniae isolates from 
hospitalized patients with IPD, such as Pan-
American Health Organization’s SIREVA II 
database. It is estimated that around 20,200 to 
33,000 children die annually in Latin America due 
to infections caused by pneumococci3. Brazilian 
data for pneumococcal disease are also scarce 
(considering the whole geographical area), but 
some studies from specific regions (Goiania, 
a Brazilian Midwest city) report that among 
children from 28 days to less than 3 years old, the 
incidence of IPD was 57.5/100,000 inhabitants 
from 2007 to 20095. 
Pneumococci are the major cause of community-
acquired pneumonia (CAP) and Brazil is among 
the 15 countries with the highest estimated 
numbers of new cases of pneumonia worldwide6. 
The mean rate of hospitalization due to CAP was 
2,100/100,000 inhabitants in Brazil, from 2000 to 
2008; 45% of them occurred in children aged less 
than 5 years and were caused by pneumococci7.  
According to the Brazilian Ministry of Health, 
it was notified of an average of 1,227 cases/
year of pneumococcal meningitis, from 2000 to 
2010, with a mortality rate around 30%7.  Among 
children under 5 years of age, the incidence was 
5.9/100,000 inhabitants, and this value increased 
to 9.5 cases per 100,000 inhabitants when younger 
children were taken into consideration (≤2 years 
old); mortality was high for both groups: 33 and 
34%, respectively5.
As an exclusively human pathogen, 
pneumococci colonize the nasopharynx, especially 
in children aged younger than 5, and transmission 
occurs by contact with respiratory secretions. From 
the primary colonization niche, they can migrate to 
other sites, such as middle ear, sinus, lung, blood, 
or cerebrospinal fluid and cause damage, leading to 
invasive disease. In this context, pneumococci have 
a robust arsenal of virulence factors, among which 
the polysaccharide capsule plays a central role8. 
Opsonophagocytosis is avoided by the presence of 
the capsule and differences in the polysaccharide 
composition distinguish over 94 distinct serotypes 
among pneumococci9. 
Commonly, antimicrobial therapy against 
pneumococci is defined empirically and the severity 
of the disease determines the medical approach10. 
Besides, specific features of microbiological 
diagnostic tests may also justify the empirical 
therapy. Indeed, some culture-based methods 
to identify S. pneumoniae have an intrinsic low 
sensitivity. For instance, blood cultures from 
patients with pneumococcal bacteremia detect 
the microorganism only in around 10 to 30% of 
cases11. On the other hand, some specimens, 
such as sputum, should be carefully analyzed, as 
low specificity may lead to false-positive results11. 
Another feature that substantiates the broad use of 
empirical therapy is the originally excellent activity 
of antimicrobials against pneumococci, especially 
the β-lactams. Pneumococci, in general, present 
very low Minimal Inhibitory Concentration (MIC) 
values13 to these drugs.  
However, this scenario has changed in recent 
years. The widespread and/or inadequate use 
of antimicrobials exerts a selective pressure on 
pneumococcal populations by picking out resistant 
isolates. In addition, selection of non-susceptible 
pneumococci may be a result of the dissemination 
of specific clones, which have an advantageous 
genetic background, including virulence and 
spread features, as well as resistance genes. 
The increased occurrence of these particular 
clones may be a natural event, where variations of 
frequency are expected during a certain period, or 
may be a result of another selective pressure force, 
such as vaccination14.   
Therefore, treatment of pneumococcal infections 
may be severely hampered by the isolation of non-
susceptible strains. Indeed, it is well established 
that the delay in the implementation of the correct 
therapy in cases of CAP significantly increases 
in-hospital mortality, as well as 30-day mortality. 
Thus, it is reasonable to conclude pneumococcal 
resistance may directly affect patient’s outcome10.
RESISTANCE MECHANISMS
According to different guidelines, therapy 
against pneumococcal infections is primarily 
based on the use of β-lactams and macrolides15-17.
Glycopeptides may also be an important 
therapeutic choice and their resistance among 
pneumococci has not been described so far. Some 
other drugs, such as fluoroquinolones, tetracycline, 
sulfamethoxazole-trimethoprim, lincosamines, and 
chloramphenicol also have good activity against 
pneumococci, but resistance against these drugs 
may occur in variable frequencies around the world 
as demonstrated bellow.
Defining resistance to some β-lactams 
(penicillins and cephalosporins) is a complex issue. 
The Clinical and Laboratory Standards Institute18 
determines breakpoints for the interpretation of 
antimicrobial susceptibility testing based on the 
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site of the infection (meningitis and non-meningitis) 
and the route of administration (oral and 
parenteral). The decision of the Institute to change 
breakpoints was based on the pharmacokinetic 
and pharmacodynamic properties of penicillin (low 
penetration across the blood-brain barrier). The 
term “penicillin non-susceptible S. pneumoniae” 
(PNSP) refers to isolates classified as resistant 
or intermediately resistant, according to current 
interpretative breakpoints19. Thus, according to 
CLSI meningitis criteria, pneumococci with MIC > 
0.06 µg/mL are considered resistant to penicillin. 
On the other hand, by non-meningitis breakpoints, 
MICs of 4 µg/mL and ≥ 8 µg/mL define the isolate 
as intermediate and fully resistant to penicillin, 
respectively18. 
β-lactams act by binding to the penicillin-
binding proteins (PBP), compromising cell wall 
formation, which leads to osmotic induced 
pneumococcal lysis20. This mechanism is highly 
effective and penicillin MICs for pneumococci 
are, in general, very low (as low as 0.01 µg/mL 
for benzylpenicillin). The first reports of higher 
penicillin MICs are from the 1960s and 1970s, but 
were neglected because of β-lactams excellent 
activity against pneumococci. Indeed, little 
regard was given to antimicrobial resistance in 
pneumococci until 1977 when the attention of the 
medical community was drawn to reports of an 
IPD epidemic in South Africa caused by highly 
resistant S. pneumoniae21. Following this report, 
multidrug-resistant (resistance to three or more 
antimicrobial classes) pneumococci were reported 
with greater frequency worldwide20,22,23.
There are six physiological PBPs in the 
pneumococcal cell: PBP1a, PBP1b, PBP2a, 
PBP2b, PBP2x, and PBP3.  Resistance to β-lactams 
is basically related to mutations in three of those 
enzymes: mutations in PBP2x and PBP2b being 
strongly related to resistance; mutated PBP1a, in 
tandem with PBP2b and PBP2x increases penicillin 
MICs further; altered PBP2a also seems to be 
related to resistance, but to a lesser degree13,24,25.
While PBP genes are highly conserved 
among pneumococci susceptible to penicillin, 
in most clinical isolates of PNSP, PBPs are 
codified by mosaic genes, which are continuous 
nucleotide sequences that differ from the non-
mosaic allele by up to 20%,13 strongly suggesting 
a non-pneumococcal origin of these genes. 
Indeed, interspecies gene transfer, followed by 
recombination events involving closely related 
commensal species, such as Streptococcus mitis 
and Streptococcus oralis seems to be the origin of 
the mosaic PBP resistant genes13,20.
Some of those mosaic genes have become 
stable in specific clones. For instance, some 
PNSP clones (Spain23F-1, Spain6B-2 and Spain9V-3) 
are internationally disseminated (see section 
“international clones” below) and present a highly 
conserved PBP2x among them; this suggests that 
the mutated gene may generate some evolutionary 
advantage. Indeed, apart from the wondrously 
transformation potential of pneumococci, 
dissemination of resistant clones are also important 
for the increase of penicillin non-susceptibility 
among pneumococci13. 
PNSP will only disseminate if a delicate balance 
occurs between antimicrobial selective pressure 
and the cost that resistance imposes on bacterial 
fitness. In this context, mutations in pbp2b carry 
an energy expenditure that affects fitness. 
However, pbp2b mutants that also carry pbp1a 
and pbp2x mutated genes not only compensate 
energetic costs, but also increase MICs, leading to 
evolutionary better adapted bacterial isolates13.  
Along with PBP changes, mutations in non-PBP 
genes also occur in PNSP and, depending on the 
selective antibiotic, distinct genes are affected19. 
A mutation in the GlcNAc deacetylase (pdgA) has 
been detected by genome sequencing in high-level 
resistant transformants obtained in four selection 
steps using chromosomal DNA of a high-level 
resistant S. pneumoniae strain. Moreover, deletion 
of the peptidoglycan O-acetyl transferase has also 
been shown to cause an extensive reduction of 
resistance in several PNSP strains26.
The worldwide increase in penicillin resistance 
coincided with an increase in macrolide resistance. 
In many parts of the world, macrolide resistance 
now exceeds penicillin13. Macrolides act by 
inhibiting protein synthesis as a result of their 
binding to the 23S portion of the ribosomal RNA27. 
Resistance is due to two major mechanisms: 
(i) alteration of the target site of the antimicrobial 
by producing a bacterial methylase codified by erm 
genes; (ii) expression of mef genes that codify an 
active efflux pump. Another mechanism may be 
associated with macrolide resistance but its clinical 
relevance is very low: through mutations in the 23S 
rRNA gene or in L4 and L22 ribosomal proteins28,29.
Indeed, the production of methylase is the 
major mechanism of macrolide resistance and it 
commonly confers the MLSB phenotype (resistance 
to Macrolides, Lincosamines and B Streptogramins). 
Two major acquired genes are responsible for this 
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resistance: erm(B) and erm(TR). The erm(TR) 
gene is a subclass of erm(A) and has a very narrow 
distribution compared to erm(B). The bacterium 
Streptococcus pyogenes seems to be the origin 
of erm(TR) and nasopharynx co-colonization 
with pneumococci. which may have allowed 
interspecies dissemination. Among pneumococci, 
after its first isolation, only a few isolates carrying 
this gene have been reported13,30. 
The presence of erm(B) usually leads to 
elevated MICs (> 64µg/mL). This gene is carried 
on members of Tn916 family of transposons (in 
pneumococci: Tn3872, Tn6002, Tn6003 and 
Tn1545), which also carry tet(M), an important 
determinant of tetracycline resistance. Although 
tet(M) is not always expressed, tetracycline 
resistance is very common among macrolide 
resistant pneumococci27,31.   
Clonal dissemination seems to play a more 
relevant role for macrolide resistance than gene 
acquisition by single strains as a result of the 
selective pressure of antimicrobial usage. Indeed, 
77.1% of erm(B) are located into Tn916 transposons 
family, suggesting that the increased occurrence of 
macrolide resistant pneumococci is a result of the 
clonal dissemination of these transposons. Indeed, 
an expressive number of pneumococci presenting 
macrolide resistance with the MLSB phenotype 
(more than 50%) belong to a few international 
pneumococcal clones: Sweden15A-25, Spain23F-1, 
Spain6B-2, clone19F-ST276, and clone19A-ST276 
(see section “international clones” below)32. 
Efflux pump, codified by mef genes, confer lower 
macrolide MICs than erm(B): 1 to 32µg/mL. In this 
case, M phenotype (only macrolide resistance) 
occurs and lincosamines and B Streptogramins 
may have activity. Among pneumococci, there 
are three related genes: the abundant mef(E) and 
mef(A), and a third gene, mef(I), with a very narrow 
distribution so far13. Mef(E) and mef(A) show 90% of 
genetic identity and present a distinct geographical 
distribution: the former is widely distributed in USA, 
Asia, and South Africa, while the latter is more 
commonly recovered from European countries, as 
well as South America33-35. 
The increase in β-lactam resistance 
spurred the development of fluoroquinolones 
active against Gram-positive pathogens. 
Fluoroquinolone resistance is increasing amongst 
pneumococci.  These drugs act by binding to the 
DNA gyrase (formed by GyrA and GyrB subunits) 
and topoisomerase IV (formed by ParC and 
ParE subunits) thus disrupting DNA synthesis. 
The primary target varies according to 
microorganisms (Gram-positive or Gram-negative) 
and the fluoroquinolone drug: among pneumococci, 
ciprofloxacin and levofloxacin act primarily in ParC 
topoisomerase subunit, while moxifloxacin firstly 
binds to GyrA DNA gyrase subunit36.
Resistance to fluoroquinolone occurs because 
of gradual accumulation of point mutations in the 
Quinolone Resistance Determinant Region (QRDR) 
of the GyrA and/or ParC. Mutations in parC QRDR 
guarantee resistance to ciprofloxacin, but not to 
the newer fluorquinolones. Indeed, QRDR parC 
mutations are the primary step in fluorquinolone 
resistance. They do not substantially increase MICs 
but enhance the risk of new mutations. On the other 
hand, isolates presenting QRDR regions of gyrA 
and parC mutated have elevated MICs (> 16µg/mL). 
Mutations in gyrB and parE are infrequent and 
seem to be unexpressive37-40.
Although some studies demonstrate an 
heterogeneous genetic background, fluoroquinolone 
resistance appears to be strongly associated with a 
single mutation in ParC and GyrA: substitution of a 
phenylalanine in positions 79 and 81, respectivelly. 
Indeed, a multicentric study demonstrated that 51% of 
pneumococci resistant to fluorquinolone showed only 
those point mutations41. 
Besides alterations in parC and gyrA nucleotide 
composition, the overexpression of efflux pumps, 
such as PmrA or the ABC pumps PatA and PatB, 
may have a role in fluorquinolone resistance. 
Although MICs in those isolates are not as high as 
the gyrA and parC mutated ones, overexpression 
of efflux pumps seems to increase chances of 
occurrence of point mutations13.
Recombination does not play a central role in 
the dissemination of fluorquinolone resistance. 
Indeed, pneumococcal QRDR has been shown to 
have low homology with viridans QRDR, a species 
more frequently related to this phenotype than 
pneumococci40. In fact, some studies demonstrated 
the occurrence of mosaic genes shared by viridans 
and pneumococci but this was not common among 
the pneumococcal population. One reason for this 
may be bacterial fitness, even though supportive 
data are lacking. Unlike macrolide resistance, 
clonal dissemination of fluorquinolone resistance 
does not have a major participation in the increase 
of this resistance and, again, bacterial fitness may 
justify this observation40.
Less clinically significant phenotypes among 
pneumococci include resistance to tetracycline, 
sulfamethoxazole plus trimethoprim, and 
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chloramphenicol. Tetracycline acts through binding 
to the 30S ribosomal unit, preventing protein 
synthesis. Resistance to this antimicrobial may be 
due to the presence of Tet(M) and, occasionally, 
Tet(O) proteins, which prevent tetracycline binding 
by a methylation reaction onto the target site; or, less 
frequently, the occurrence of efflux pumps, Tet(K) 
and Tet(L), respectivelly41,42. The tet(M) gene is 
located in genetic mobile elements widely found and 
transmitted among many Gram-positive bacteria 
justifying the frequent occurrence of this phenotype 
in pneumococcal population. Efficacy and low 
cost are the main reasons for sulfamethoxazole-
trimethoprim therapy against pneumococci, 
especially in developing countries, where reports 
of resistance are increasing. Prophylactic usage of 
this antimicrobial to prevent secondary infections 
in HIV positive patients may also explain the high 
rates of resistance observed. Sulfamethoxazole-
trimethoprim acts on folic acid synthesis and 
mutations in genes (folA and folP) that codify the 
binding target of these drugs are responsible for 
resistance43. Finally, chloramphenicol resistance 
occurs through production of chloramphenicol 
acetyltransferases, codified by cat genes. The 
enzyme converts the antimicrobial into a non-
functional molecule, preventing chloramphenicol 
binding to 50S ribosomal subunit44. 
Table 1 summarizes the main resistance 
mechanisms to antimicrobials in S. pneumoniae.
PREVALENCE OF RESISTANCE 
Global 
Although the incidence of IPD caused by 
PNSP, pneumococci resistant to erythromycin 
or multiresistant pneumococci had decreased 
significantly after the introduction of the 7-valent 
pneumococcal conjugate vaccine (PCV7), 
including serotypes in 2000, the increased isolation 
of resistant non-vaccine serotypes promoted a rise 
in the frequency of resistant pneumococci in some 
parts of the world45. Indeed, from 1998 to 2003, the 
proportion of PNSP decreased from 32% to 19.4%, 
followed by a post-vaccine increase to 30.1% in 
2005. Some serotypes are consistently related to 
the decrease of the susceptibility, especially the 
so-called pediatric serotypes (6A, 6B, 9V, 14, 19A, 
19F, and 23F), as well as some other non-vaccine 
serotypes: 19A and 35B46,47. 
A recent multicentric study encompassing 2,173 
IPD-recovered pneumococci from patients of all 
ages and from all continents (2004-2009) showed 
that 33.3% of all isolates were non-susceptible 
to penicillin (MIC < 0.06 µg/mL). Resistance to 
erythromycin was quite lower (22.9%) and 16.2% 
of all S. pneumoniae were resistant to both 
penicillin and erythromycin. Isolates resistant to 
levofloxacin represented only 0.5% of the total. 
Some serotypes were significantly associated with 
PNSP: 19A, 6A, 19F, 14, 6B, 9V, 35B, 23A, and 
15A. Similarly, serotypes 19A, 6A, 15A, 19F, 9V, 
6B, and 14 had a statistically significant relationship 
with erythromycin resistance23.
If the populations with the highest risk for 
pneumococcal infections are taken into consideration21, 
resistance to penicillin considerably increased in 
all continents compared to the general (all ages) 
population23. Brandon and Dowzicky included in their 
study pneumococci recovered from clinically relevant 
sites of pediatric populations (0 to 18 years old), 
from 2004 to 2011. Globally, PNSP was 46.1% and 
levofloxacin remained very low 0.3%22.
Geographic occurrence of resistance is not 
homogeneous and both selective pressure by 
antimicrobial use and circulation of some specific 
clones/serotypes are responsible for the differences 
in the prevalence of resistant pneumococci 
worldwide14.
Hackel et al. demonstrated that, for patients 
of all ages, erythromycin resistance ranges from 
15.3% to 28.8% among all continents, with the 
lowest frequency in Latin America and the highest 
among Asian countries. On the other hand, Africa 
presents the highest frequency of isolation of 
PNSP (64.3%), while only 18.6% of pneumococci 
Table 1: Mechanisms of resistance against the most clinically relevant antimicrobials.
Antimicrobial Resistance mechanism Reference
Penicillin Mutations in pbp genes = mosaic genes 12
Erythromycin Expression of erm (methylation) and/or mef (efflux pumps) genes 27
Tetracycline Expression of tet genes: methylation [tet(M) and tet(O)] and/or efflux pump [tet(K) and tet(L)] 41
Fluoroquinolones Mutations in QRDR of parC and gyrA. 35
Chloramphenicol Expression of cat gene (acetyltransferases) 43
Sulfamethoxazole-trimethoprim Mutations in folA and folP 42
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recovered from European countries show this 
phenotype23. 
Geographical variation of frequency among 
the pediatric population presents a similar pattern. 
The lowest frequency of isolation of PNSP (34.4%) 
occurred in Europe, with a frequency almost twofold 
higher than that observed among all ages (18.6%). 
Africa had, once again, the highest rates of PNSP, 
85.7%. All continents but Africa (no resistance 
detected) had levofloxacin-resistant pneumococci 
in a low frequency of isolation: from 0.2 in Europe 
to 1.1% in the Middle East22. 
Although data from Europe commonly 
demonstrate low rates of PNSP, a large recent 
European study including more than 21,000 
pneumococcal isolates showed that some countries 
may have frequencies of PNSP and resistance 
to macrolides as high as 42.2% and 38.1%, 
respectively. Once again, serotypes 14, 19A, and 
19F were the most commonly involved48.  
Some other limited studies have shown quite 
different frequencies of resistance, especially 
if differentiated populations are taken into 
consideration. For instance, pneumococci 
recovered from nasopharynx of healthy children 
in China revealed 39.4% of PNSP during 2012 to 
201349. In the same study, all 175 pneumococcal 
isolates were resistant to erythromycin. Over again, 
serotype 19F (precisely Taiwan19F-14 clone) was 
significantly associated with β-lactam resistance49. 
Resistance to erythromycin was also extremely 
high among Japanese pneumococcal isolates, 
recovered from noninvasive or colonization sites 
during 2011: 96.8%, and serotypes 23F and 6B 
were the most commonly related to this phenotype. 
On the other hand, resistance to penicillin was 
very low50. 
Other studies focusing on pneumococcal 
from carriage demonstrate a similar scenario51-55, 
although some specific regions may show higher 
frequencies. Indeed, frequency of PNSP was 78.6% 
among isolates from healthy Korean children56.
Of note, despite the worrisome occurrence of 
PNSP considering CLSI meningitis breakpoints, 
isolates presenting non-susceptibility to penicillin 
following non-meningitis breakpoints (MIC ≥4µg/mL) 
are very low worldwide48. 
BRAZIL
According to SIREVA II, the prevalence of PNSP 
(MIC > 0.06 µg/mL) in Brazil was 25.7%, while 
11.5% showed erythromycin resistance57. Some 
regional studies present quite similar data. Of note, 
all studies used CLSI meningitis breakpoints to 
define PNSP.  
Andrade et al. evaluated pneumococci 
recovered from children with IPD previous to 
implementation of vaccination in Brazil (207-2009) 
and identified 13.3% as PNSP, all of them belonging 
to serotypes included in PCV7. No levofloxacin 
resistant isolates were found and 13.3% presented 
macrolide resistance5. 
On the other hand, Mott et al. firstly evaluated 
159 invasive pneumococcal isolates recovered in 
post-vaccination period (2010 to 2012) in the 
country. An increase of PNSP was observed 
(21.4%) compared to the above-cited study and 
serotypes 14, 9V, 19F, 23F, and 19A were the most 
commonly related to this phenotype. Only one 
isolate, belonging to serotype 19A, had a MIC=4 
mg/mL to penicillin (intermediate resistance, 
according to CLSI criteria for non-meningitis), and 
isolates showing MICs≥8 mg/mL were not found. 
Resistance to erythromycin was 12% and only one 
isolate was resistant to fluoroquinolone35. 
Among pneumococci recovered from patients 
with meningitis during 2000-2007, the frequency of 
PNSP was very similar (22.2%) but erythromycin 
resistance was considerably lower: 0.8%58. Similar 
results were found when pneumococcal from 
carriage were taken into consideration59. 
Resistance rates to tetracycline, 
chloramphenicol, and sulfamethoxazole-
trimethoprim were found to be more heterogeneous 
in different Brazilian studies5,35,57,58,60,61. As an 
example, non-susceptibility to sulfamethoxazole-
trimethoprim varied from 28.5%56 to 80%5, while 
the percentage of pneumococci non-susceptible 
to tetracycline seems to be more homogeneous 
(around 20-30%)35,58.
Continuous surveillance of pneumococci 
focusing on antimicrobial susceptibility, as well 
as serotype distribution is of great concern in 
developing countries such as Brazil and should be 
performed systematically to better understand the 
impact of vaccination on resistance rates. 
PNEUMOCOCCAL INTERNATIONAL CLONES 
AND THE INFLUENCE OF VACCINATION IN 
THE DISSEMINATION OF RESISTANCE
Although S. pneumoniae is a genetically 
diverse species capable of expressing over 94 
different capsular types9, only a limited number of 
these serotypes associated with a few pandemic 
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clones have been responsible for the increase of 
pneumococcal drug resistance worldwide14. The 
origin of these drug resistant clones is believed 
to be the nasopharynx of young children, from 
where they are transferred from person-to-
person. These circumstances, combined with 
frequent antibiotic use, constitute ideal conditions 
for the selection, amplification, and transmission 
of drug-resistant clones62. 
Created in 1997, the Pneumococcal Molecular 
Epidemiology Network (PMEN - http://web1.sph.
emory.edu/PMEN/) intended to develop a global 
surveillance of antibiotic-resistant Streptococcus 
pneumoniae clones. In order to standardize the 
nomenclature and classification of these clones, 
their names are composed by the location of 
the first isolation, the serotype (superscript), 
plus a number indicating the chronological order 
of nomination by PMEN. For example, the first 
PMEN clone was isolated in Spain and the strains 
were serotyped as 23F: Spain23F-1. Forty-three 
important disease-causing clones have been 
identified63. Although resistant strains are the 
primary focus of surveillance, some susceptible 
clones with relevant importance in invasive 
disease worldwide are also considered by PMEN. 
Table 2 presents characteristics of PMEN clones 
resistant to penicillin considering meningitis 
breakpoints (MIC> 0.06 µg/mL). 
To be included into the network, clonality 
must be determined based on Pulsed-Field Gel 
Electrophoresis (PFGE), Multilocus Sequence 
Typing (MLST), and Penicillin-Binding Protein 
(PBP) fingerprinting results. Despite the high 
discriminatory power of PFGE, this technique 
has low reproducibility and, consequently, data 
may not be homogeneous among geographically 
distinct laboratories. On the other hand, MLST 
generates unambiguous data, making it easy to 
compare strains from different regions. Indeed, it 
increases the understanding of the pneumococcal 
population dynamics and their patterns of 
dissemination worldwide.
Apart from the β-lactams, resistance to 
erythromycin and tetracycline are the most prevalent 
phenotypes among PMEN clones (19/43; 44.2%). 
Table 2: Pneumococcal Molecular Epidemiology Network clones presenting resistance to penicillin (meningitis breakpoints: 
MIC > 0.06 µg/mL).
PMEN clone ST Serotype Vaccine
Susceptibility profile c (MIC in µg/mL)
PEN CTX ERY CLI CHL TET SXT
Spain23F-1 81 23F all b 1 1.5 0.25 0.19 16 64 2
Spain6B-2 90 6B all 0.5 0.75 0.19 0.19 16 48 2
Spain9V-3 156 9V all 1.5 0.75 0.125 0.19 3 0.5 1.5
Tennessee23F-4 37 23F all 0.125 32 32 0.125 3 0.25 2
Spain14-5 18 14 all 1.5 1 0.19 0.125 32 24 0.25
Hungary19A-6 268 19A PCV13 1 0.75 >256 >256 24 48 3
S.Africa19A-7 75 19A PCV13 0.19 0.094 0.25 0.19 4 1 4
S.Africa6B-8 185 6B all 0.19 0.125 0.19 0.19 2 0.5 1.5
CSR14-10 20 14 all 8 1 >256 >256 32 48 0.25
CSR19A-11 175 19A PCV13 6 0.5 >256 >256 24 64 2
Finland6B-12 238 6B all 4 0.75 >256 >256 8 64 6
S.Africa19A-13 41 19A PCV13 1.5 0.5 >256 >256 24 48 4
Taiwan19F-14 236 19F all 2 0.75 16 0.25 16 48 2
Taiwan23F-15 242 23F all 0.75 0.75 >256 >256 4 48 0.25
Poland23F-16 173 23F all 8 4 >256 0.25 16 64 1.5
Maryland6B-17 384 6B all 1.5 1 24 0.19 3 0.75 2
Tennessee14-18 67 14 all 4 12 >256 >256 3 32 2
N.Carolina6A-23 376 6A PCV13 1 0.75 4 0.19 3 0.5 1
Utah35B-24 377 35B NONE 1 0.75 0.125 0.125 3 0.38 0.38
Denmark14-32 230 14 PCV7 1 0.75 0.125 0.125 3 64 1.5
NorwayNT-42 344 NT NONE 0.094 0.125 4 0.064 2 32 0.38
USANT-43 448 NT NONE 0.094 0.094 4 0.094 3 32 0.25
a ST: sequence type, according to MLST results
b All = PCV7, PCV10 and PCV13
c * PEN = penicillin; CTX = ceftriaxone; ERY = erythromycin; CLI = clindamycin; CHL = chloramphenicol; TET = tetracycline; SXT = sulfamethoxazole-trimethoprim
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Considering CLSI meningitis criteria for penicillin 
and ceftriaxone, 20 (46.5%) and 16 (37.2%) 
clones exhibit nonsusceptibility: MIC ≥ 0.12µg/mL 
and ≥ 2µg/mL, respectively. If non-meningitis 
breakpoints are taken into consideration, clones 
CSR14-10, CSR19A-11, Finland6B-12, Poland23F-16, 
and Tennessee14-18 are non-susceptible to penicillin 
(MICs ≥ 4µg/mL). Poland23F-16 and Tennessee14-18 
are also fully resistant to ceftriaxone (MICs ≥ 4µg/mL). 
Besides, despite its penicillin susceptibility, 
Tennessee23F-4 is characterized by a very high 
ceftriaxone MIC (32 µg/ml). In general, these 
β-lactams nonsusceptible clones are multiresistant 
and their occurrence worldwide may strongly 
compromise empirical therapy against IPD. 
PCV7 was particularly designed against the 
most prevalent and/or resistant serotypes, i.e. 
4, 6B, 14, 18C, 19F, and 23F, which are widely 
distributed around the world. Indeed, most PMEN 
clones (51.2%) encompass pneumococci from 
PCV7, especially serotypes 14, 6B and 23F (17/22; 
72.3%), which is not surprising, since vaccine 
formulations were developed precisely against 
the serotypes most commonly related to IPD 
worldwide and/or those with worrisome resistance 
characteristics. PCV10 (PCV7 serotypes plus 1, 
5 and 7F) and PCV13 (PCV10 serotypes plus 3, 
6A and 19A) comprise 65.1% (28/43) and 81.4% 
(35/43) of the international pneumococcal clones, 
respectively. Of note, 18.6% of PMEN clones are 
composed of serotypes not included in any vaccine 
formulation currently available (including two non-
typable clones: NorwayNT-42 and USANT-43) and 
they will be further discussed below. 
Among all 43 PMEN clones, the most widely 
distributed seem to be Spain23F-1, Spain6B-2, and 
Spain9V-3. Spain23F-1 predominantly circulates 
as a vaccine serotype 23F, multilocus sequence 
type 81 (ST81). However, ST81 has also been 
associated with several other serotypes, including 
both vaccine and non-vaccine types64,65. After 
the first isolation, Spain23F-1 disseminated 
worldwide64,66-69. Indeed, by the late 1990s, it was 
estimated that approximately 40% of the penicillin 
non-susceptible pneumococci circulating in the 
USA were members of this clone70, corroborating 
the spread of penicillin resistance determinants 
among other pneumococcal clones. Besides 
penicillin, Spain23F-1 is also commonly associated 
with fluoroquinolone resistance and some authors 
have suggested that genetic determinants for this 
resistance have been donated from Spain23F-1 to 
numerous unrelated pneumococcal clones71.
It has been well demonstrated by Wyres et  al. 
that Spain23F-1 and related clonal variants (all 
belonging to the same clonal complex - CC81), 
exhibit extraordinary genetic diversity, which largely 
results from hundreds of recombination events72. 
These features indicate rapid genomic evolution 
and presumably allow rapid response to selective 
pressures such as those imposed by vaccine and 
antibiotic usage65. 
Indeed, although antibiotics are among the most 
influential global public health successes, selective 
pressures imposed by them drive bacterial genomic 
evolution. Spain23F-1 is an excellent example of a 
bacterium that has become resistant to multiple 
antibiotics and that has evolved to become 
very successful in colonization, transmission, 
and causing disease. Moreover, Spain23F-1 has 
subsequently shared its successful DNA with other 
unrelated pneumococci72.
On the other hand, Spain9V-3 belongs to ST156 
(CC156), which, according to the MLST database, 
has been associated with a considerable diversity 
of capsular types (14, 9V, 19F, 11A, 9A, 15C, 13, 
19A, and 15B), suggesting a high tendency of this 
clonal cluster to undergo capsular switching events. 
CC156, one of the largest CC presently found 
in the MLST database with frequent occurrence 
around the world63, including Latin America and 
Brazil61,73,74, is globally and consistently associated 
with important resistance profiles, including non-
susceptibility to penicillin75. 
As PCV7 has been widely implemented 
worldwide, it is expected that these traditional 
resistant clones will lose ground because of 
selective pressure, given advantages to other 
clones/serotypes. A classic example of this natural 
biological event was the emergence of serotype 
19A in both carriage and invasive disease soon 
after PCV7 implementation in the USA76. Of note, 
some clones of serotype 19A are consistently 
non-susceptible to penicillin, as well as resistant 
to other antimicrobials77. As a consequence, this 
capsular switching event dramatically increased the 
occurrence of penicillin non-susceptible isolates in 
many different regions of the world.  
However, serotype 19A also increased in 
regions without vaccine selective pressure, 
suggesting the participation of other factors, such 
as temporal variations, dissemination of some 
specific clones, and antimicrobial pressure78. Four 
PMEN international clones are related to serotype 
19A: Hungary19A-6 (ST268), S.Africa19A-7 (ST75), 
CSR19A-1 (ST175), and S.Africa19A-13 (ST41). 
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All but one (S.Africa19A-7) are multiresistant, 
including non-susceptible to penicillin (meningitis 
breakpoints). 
Besides those above-mentioned clones, genotypic 
characterization of serotype 19A isolates by MLST 
showed that there are five major CC associated with 
them: CC81, CC193, CC199, CC276, and CC32078. 
ST320 (CC320), derived from Taiwan19F-14 (ST236) 
by capsular switching events, has become prevalent 
in many countries, and is strongly related to penicillin 
resistance76,80-83. Recently, it was observed that the 
genetic background of ST320 provides advantages 
associated with improved colonization in the 
nasopharynx when compared to ST19977, another 
well-established serotype 19A clone, prevalent in the 
USA previously to PCV7. Indeed, this advantage may 
be responsible for the rapid shift of ST199 to ST320 in 
the USA soon after the introduction of PCV776.  
As mentioned above, along with those antibiotic-
resistant clones, PMEN also focus on some important 
disease-causing susceptible clones, such as the 
following related to serotypes included in one of the 
conjugate pneumococcal vaccines: Sweden1-27 
(ST217), Sweden1-40 (ST304), Netherlands3-31 
(ST180), Sweden4-38 (ST205), Portugal6A-41 
(ST327), S.Africa6B-8(ST185), Netherlands7F-39 
(ST191), and Colombia23F-26 (ST338). 
Serotype 1 ranks among the most prevalent 
invasive serotypes in many countries84-87 causing 
severe episodes of pneumonia and empyema 
in children88. In Brazil, since 1977, serotype 1 
has been identified as one of the most frequent 
pneumococci causing severe infections in both 
adult and pediatric patients89. 
Some specific features are responsible for the 
epidemiological relevance of serotype 1, despite 
its susceptibility to most antimicrobials. First, a low 
colonization frequency, even in populations in which 
serotype 1 is a frequent cause of pneumococcal 
infections90,91. In addition, serotype 1 has the ability 
to cause outbreaks in communities and in crowded 
and closed institutions92. Besides, serotype 1 
markedly presents low genetic diversity among the 
isolates, which has been associated with the short 
duration of carriage and/or a low density of this 
serotype in the nasopharynx, resulting in a reduced 
opportunity to exchange genes between strains93. 
Another serotype with high invasiveness power 
is serotype 3, which has been related with increased 
mortality in different regions94-96. Considering its 
genetic background, strains of serotype 3 belonging 
to ST180 have been associated with significant 
mortality97. Therefore, the high frequency of 
isolation of this serotype/ST and its relation with 
mortality needs continued surveillance to monitor 
for increases in this serotype post-PCV10 as this 
data may be important to consider the use of 
PCV13 in some regions.
Although somewhat controversial, serotype 
7F also appears to be associated with high case-
fatality95. Some authors have observed serotype 
7F as one of the main serotypes associated with 
replacement following PCV7 introduction, through 
clonal expansion98,99. Pichon et al. demonstrated 
ST191 (serotype 7F) as the most prevalent clone 
causing meningitis 3 years after the introduction 
of PCV7 in England and Wales99. From reported 
studies, serotype 7F seems to be very rare in the 
nasopharynx of Brazilian children59,73,90. Besides, 
as it is part of the currently available pneumococcal 
vaccine (PCV10), it may not represent a worrisome 
occurrence in Brazil. 
PCV7 was introduced in the United States 
in 2000, when almost half of all IPD was caused 
by pneumococci resistant to penicillin and/or 
macrolides100. As expected, following the 
introduction of pneumococcal vaccination, there 
was a substantial reduction in penicillin non-
susceptible pneumococci occurrence101. However, 
subsequently to PCV7 usage, there has been an 
increase in pneumococcal disease due to non-PCV7 
type pneumococci102, many of which are now also 
penicillin non-susceptible, such as 19A and 6A, that 
are part of other vaccine formula, as well as other 
serotypes absent in any pneumococcal vaccine 
so far103. Therefore, despite the unquestionable 
beneficial effects of vaccination, the problem of 
resistance among pneumococci is far from solved. 
In this context, eight PMEN clones include 
strains with serotypes not present in any 
of the currently available vaccine formula. 
They are related to the following STs: ST53 
(Netherlands8-33), ST63 (Sweden15A-25), 
ST193 (Greece21-30), ST199 (Netherlands15B-37), 
ST218 (Denmark12F-34), ST377 (Utah35B-24), 
ST448 (USANT-43), and ST344 (NorwayNT-42). In 
general, they are multi-susceptible.
Some molecular characteristics of the 
Netherlands8-33 may explain its well-succeeded 
clonal spread: Jefferies et al. identified a 
pneumolysin allele 5 in ST53, a common 
worldwide-distributed ST related to serotype 8, 
that could facilitate the clonal expansion of those 
strains104. Besides, some authors include serotype 
8 into the group of more invasive and/or the ones 
related to the worst outcomes. Therefore, as it 
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may become an important serotype in the post-
vaccination era, and as antimicrobial usage may 
stimulate resistance occurrence, surveillance of 
these widely distributed serotype 8 clones is a 
subject of major concern. 
Grabenstein et al. performed a systematic 
review to characterize differences in serious 
outcomes between pneumococcal serotypes. The 
authors show that serotype 8 was consistently 
related to an increase in severity of the disease, as 
well as serotype 15B105. The Netherlands15B-37 is 
part of ST199, which also encompasses serotype 
19A (among others), strongly related to penicillin 
resistance. The occurrence of the same genetic 
background (ST199) between serotype 19A and 
serogroup 15 is indicative of capsular switching. 
Sweden15A-25 belongs to ST63, which is 
worldwide distributed, including Latin America. This 
ST is essentially related to serotypes 15A, 14, 19F, 
and 19A. The capsular type 15A strain was found 
to only differ from the fully sequenced 19F clinical 
isolate G54 in the chemical composition of the 
capsular polysaccharide indicating that this lineage 
has the capacity to undergo in vivo capsular switch. 
A capsular switch may produce “vaccine escape” 
recombinants94 that can avoid the vaccine-induced 
immune pressure, allowing pneumococcal survival 
as a species. 
Of note, the serotype 19A (ST276) and 
15A (ST63) clones have been identified as the 
S. pneumoniae clonal types most frequently 
recovered from pneumococcal infections in 
countries that introduced the PCV7 vaccine80,106,107. 
For unknown reasons, representatives of the third 
major colonizing clone with serotype 6A (ST2191) 
have not been recovered from pneumococcal 
disease. In contrast, colonization by each of the 
three major non-PCV7 clonal lineages has been 
widely reported108.
Although Utah35B-24 (ST377) presents a 
susceptible phenotype (albeit resistance to 
penicillin, considering meningitis CLSI criteria – 
MIC 1µg/mL), some post-vaccine works have 
demonstrated a relationship between this 
serotype and resistant profiles109, as well as 
increased occurrence of this serotypes (and 
others such as 15A and 15B) in both carriage and 
invasive disease. Surveillance of serogroup 15, 
considering dissemination and resistance, may 
be of great relevance to the development of new 
vaccine formulations. 
Similarly for serotype 8, serotype 12F has 
demonstrated increased occurrence after 
vaccination in some regions. Besides, it has been 
shown to cause outbreaks in human populations 
with identifiable risk factors110. This serotype has a 
high case/carriage ratio (CCR), i.e., it is a hyper 
invasive serotype, rarely found in nasopharynx73,110. 
One could expect that, after vaccine selective 
pressure, the pneumococcal population is supposed 
to suffer considerable changes, which may affect 
the behavior of such non-vaccine serotypes. 
Based on the above, it is reasonable to 
conclude that the pneumococcal population 
is constantly changing, either because of 
biologically expected temporal changes or due 
to selective pressure exerted by vaccination and 
antibiotics. This situation may significantly alter 
the occurrence of antimicrobial resistance, and, 
in this context, epidemiological surveillance is 
consistently required to understand and monitor 
these changes, as they may directly affect patient 
care, as discussed below.
CONCLUSION
Pneumococcal infections are treated 
empirically. Limitations in the diagnostic methods, 
together with the severity of disease contribute to 
this procedure. Surveillance studies are crucial 
to define the prevalence of resistant strains 
both globally and in a particular region. Data 
obtained from such studies are generated by 
culture-dependent methods. Although different 
clones of PNSP are internationally distributed, 
and considering diseases other than meningitis, 
the prevalence to penicillin is quite low, making 
this old, safe, and inexpensive drug an attractive 
first choice to treat pneumococcal infections. The 
widespread use of conjugate vaccines among 
children, influencing the circulation of resistant 
clones, reinforces the need of surveillance studies 
to define the prevalence of resistance. 
Finally, it is important to consider that almost 
all that is known about pneumococcal resistance 
comes from culture-insensitive methods. Culture 
independent methods are, in a certain sense, 
modifying some concepts about pneumococcal 
disease and once applied to the detection 
of resistant strains, they may also contribute 
to a better knowledge about resistance in 
pneumococci. 
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